Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CNPY2 siRNA
- Development stage
- Preclinical
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Parenteral
01
Overview
CNPY2 siRNA is an experimental research reagent designed to silence the expression of the Canopy FGF Signaling Regulator 2 (CNPY2) gene through RNA interference (RNAi). CNPY2 is a protein involved in the unfolded protein response (UPR) and fibroblast growth factor (FGF) signaling, and its overexpression has been linked to tumor progression, angiogenesis, and metabolic reprogramming in various diseases. In preclinical oncology models, knockdown of CNPY2 using siRNA has been shown to inhibit cell proliferation, migration, and invasion in cancers such as hepatocellular carcinoma, renal cell carcinoma, and non-small-cell lung cancer. Additionally, recent research suggests a role for CNPY2 in regulating glycolysis and pulmonary vascular remodeling in pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF). It is currently used exclusively as a laboratory tool and has not entered formal clinical development.
- Other names
- si-CNPY2si-CNPY-2si-CNPY 2CNPY2-siRNACNPY-2-siRNACNPY 2-siRNA
02
Targets
Canopy FGF signaling regulator 2 mRNA (CNPY2 mRNA)
Beyond the preview
Go deeper on CNPY2 siRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CNPY2 siRNA.